01 1Apriso
02 3Asacol
03 4Asacol/Delzicol
04 1Canasa
05 4Canasa/Salofalk
06 1Delzicol
07 3Etiasa
08 7Lialda/Mezavant
09 2Lialda/Mezavant/Mesavancol
10 2Mezavant/Mesavancol/Lialda
11 7Pentasa
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2017 Revenue in Millions : 246
2016 Revenue in Millions : 415
Growth (%) : -41
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2017 Revenue in Millions : 181
2016 Revenue in Millions : 196
Growth (%) : -8
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2018 Revenue in Millions : 177
2017 Revenue in Millions : 246
Growth (%) : -28%
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2018 Revenue in Millions : 187
2017 Revenue in Millions : 181
Growth (%) : 3%
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2016 Revenue in Millions : 415
2015 Revenue in Millions : 618
Growth (%) : -33
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2016 Revenue in Millions : 196
2015 Revenue in Millions : 156
Growth (%) : 26
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2019 Revenue in Millions : 113
2018 Revenue in Millions : 177
Growth (%) : -36
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2019 Revenue in Millions : 48
2018 Revenue in Millions : 187
Growth (%) : -74